Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · IEX Real-Time Price · USD
25.22
-0.83 (-3.19%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $35.47M in the twelve months ending March 31, 2024, down -87.00% year-over-year. In the fiscal year ending September 30, 2023, Arrowhead Pharmaceuticals had annual revenue of $240.74M, a decrease of -1.03%.
Revenue (ttm)
$35.47M
Revenue Growth
-87.00%
P/S Ratio
88.30
Revenue / Employee
$67,568
Employees
525
Market Cap
3.13B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
Sep 30, 2011 | 296.14K | - | - |
Sep 30, 2010 | 0 | - | - |
Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
Sep 30, 2005 | 590.68K | 394.38K | 200.90% |
Sep 30, 2004 | 196.31K | - | - |
Sep 30, 2003 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Surgery Partners | 2.79B |
Amedisys | 2.25B |
Neogen | 929.24M |
HUTCHMED (China) | 838.00M |
Corcept Therapeutics | 523.53M |
iRhythm Technologies | 513.17M |
Denali Therapeutics | 295.39M |
Olink Holding AB (publ) | 170.89M |
ARWR News
- 7 days ago - Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course - Business Wire
- 7 days ago - Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial - Business Wire
- 8 days ago - Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE - Business Wire
- 8 days ago - 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - Benzinga
- 4 weeks ago - Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia - Business Wire